[1] 罗胜兰,俞敏,龚巍巍.甲状腺癌的流行现况及其危险因素[J].中国预防医学杂志,2013,14(4):317-322.[2] Tuttle RM, Ball DW, Byrd D, et al. Thyroid carcinoma. J Natl Compr Canc Netw. 2010;8(11):1228-1274. [3] 钱波,蔡寒清,冯洁.干细胞,肿瘤干细胞与肿瘤发生[J].世界华人消化杂志,2007,15(13):1526-1531.[4] Dalerba P, Clarke MF. Cancer stem cells and tumor metastasis: first steps into uncharted territory. Cell Stem Cell. 2007;1(3): 241-242.[5] 赛恒,吴岩,毕力夫.甲状腺肿瘤干细胞与甲状腺肿瘤治疗[J].中国民康医学,2015,27(14):150.[6] 邢越,黎洪浩.甲状腺癌干细胞研究进展[J].岭南现代临床外科, 2013,13(5):458-460.[7] Hermanns HM, Radtke S, Haan C, et al. Contributions of leukemia inhibitory factor receptor and oncostatin M receptor to signal transduction in heterodimeric complexes with glycoprotein 130. J Immunol. 1999;163(12):6651-6658.[8] Johnson RW, Finger EC, Olcina MM, et al. Induction of LIFR confers a dormancy phenotype in breast cancer cells disseminated to the bone marrow. Nat Cell Biol. 2016;18(10): 1078-1089.[9] Luo Q, Wang C, Jin G, et al. LIFR functions as a metastasis suppressor in hepatocellular carcinoma by negatively regulating phosphoinositide 3-kinase/AKT pathway. Carcinogenesis. 2015;36(10):1201-1212.[10] 李欢欢,李素平,游金辉.分化型甲状腺癌肺转移临床诊断研究进展[J].2014,31(4):950-954.[11] 张雪梅,吴岩,赛恒.干细胞治疗甲状腺癌的探索[J].中国民康医学, 2015,27(14):153.[12] Arthan D, Hong SK, Park JI. Leukemia inhibitory factor can mediate Ras/Raf/MEK/ERK-induced growth inhibitory signaling in medullary thyroid cancer cells. Cancer Lett. 2010;297(1): 31-41.[13] Chen D, Sun Y, Wei Y, et al. LIFR is a breast cancer metastasis suppressor upstream of the Hippo-YAP pathway and a prognostic marker. Nat Med. 2012;18(10):1511-1517.[14] 徐晓波,刘文勇.甲状腺癌CD133表型研究进展[J].临床和实验药物杂,2011,10(6):466-467.[15] Zhou L,Wei X,Cheng L,et al. CD133, one of the markers of cancer stem cells in Hep-2 cell line. Laryngoscope. 2007;117(3): 455-460.[16] Zito G, Richiusa P, Bommarito A, et al. In vitro identification and characterization of CD133(pos) cancer stem-like cells in anaplastic thyroid carcinoma cell lines. PLoS One. 2008;3(10): e3544.[17] Lee SY, Jeong EK, Ju MK, et al. Induction of metastasis, cancer stem cell phenotype, and oncogenic metabolism in cancer cells by ionizing radiation. Mol Cancer. 2017;16(1):10.[18] Thiery JP, Acloque H, Huang RY, et al. Epithelial-mesenchymal transitions in development and disease. Cell. 2009;139(5): 871-890.[19] 刘志娴,魏尔清,卢韵碧.上皮-间质转化在肿瘤发生发展中的作用研究进展[J].浙江大学学报,2015,44(2):211-216.[20] Huang R, Zong X. Aberrant cancer metabolism in epithelial-mesenchymal transition and cancer metastasis: Mechanisms in cancer progression. Crit Rev Oncol Hematol. 2017;115:13-22.[21] Liu F, Gu LN, Shan BE, et al. Biomarkers for EMT and MET in breast cancer: An update. Oncol Lett. 2016;12(6):4869-4876.[22] Groblewska M, Siewko M, Mroczko B, et al. The role of matrix metalloproteinases (MMPs) and their inhibitors (TIMPs) in the development of esophageal cancer. Folia Histochem Cytobiol. 2012;50(1):12-19.[23] Watanabe H. Extracellular matrix--regulation of cancer invasion and metastasis.Gan To Kagaku Ryoho. 2010;37(11):2058-2061. |